PAI-1 activity was highest in ITP patients, with a statistically significant difference in comparison to HC. Bleeding severity was higher and more ITP patients had a thrombosis history compared to HC, whereas there was no difference in comparison to TPC. Primary ITP patients had a higher BMI than HC. Results: In total, 37 primary ITP patients, 18 TPC and 156 healthy controls were analyzed (Table 1). Bleeding severity was measured using the ITP-specific ITP-ISTH BAT (Rodeghiero et al.

PAI-1 (PAI-1 Actibind ELISA, Technoclone, Vienna, Austria) and α2-antiplasmin by the chromogenic STA Stachrom antiplasmin assay (Diagnostic Stago, Asnieres, France) were measured. Platelet poor plasma samples were measured in duplicates for each patient and control. A clot formation and lysis assay (CLA) was performed according to the recommendations of the ISTH SSC. Informed consent was obtained from all individuals before study inclusion. Methods: Patients from the Vienna ITP biobank (EC 1843/2016), a multi-centric study including adult patients with primary ITP were investigated and compared to age- and sex-matched control groups: TPC with thrombocytopenia after chemotherapy and HC. Furthermore, associations with bleeding severity and previous thrombotic events were investigated. Patients have heterogeneous bleeding phenotypes, which are not only determined by platelet counts, also a paradoxically increased thrombotic risk has been observed.Īim: To investigate, whether the fibrinolysis inhibitors plasminogen activator inhibitor-1 (PAI-1) and α2-antiplasmin are associated with impaired plasma clot lysis in primary ITP patients in comparison to non-immunologic thrombocytopenic controls (TPC) and healthy controls (HC). Introduction: Primary immune thrombocytopenia (ITP) is an orphan disease characterized by very low platelet counts.

Stachrom at iii stago notice